Key result
In 81 hemodialysis patients followed for 20 months, increased serum cTnT was not associated with an increase in mortality.
Answers are grounded in this paper and cite their sources.
Haller et al. (1) have strengthened the argument that the increased serum cardiac troponin T (cTnT) found in many patients with end-stage renal disease (ESRD) originates in heart muscle and not regenerating skeletal muscle, as suggested by others (2). We recently measured serum cTnT using the Elecsys 2010 immunoassay system (Boehringer Mannheim), a method that is specific for cTnT (3), and creatine kinase MB isoenzyme (CK-MB) mass (Dade Stratus II immunoassay system) in 71 stable patients with ESRD. The serum cTnT was >0.1 μg/L in 37 (52%) of them, and interestingly, cTnT and CK-MB were significantly correlated (Fig. 1); in all 14 patients with serum CK-MB >4 μg/L the serum cTnT was >0.1 μg/L. This is consistent with a common source of these proteins, although of course it does not indicate whether the common source is heart or skeletal muscle. Troponin T vs CK-MB in 71 hemodialysis patients. r2 = 0.556; P <0.001. We think that the most important question in the cTnT-ESRD debate is the prognostic importance of this biochemical abnormality, and particularly whether these patients require some modification of their treatment. We have followed 81 hemodialysis patients over a 20-month period and have found no increase in mortality in those with increased cTnT (7 deaths from 43 patients) compared with those with cTnT within reference values (7 deaths from 38 patients). Other researchers have found otherwise, with increased serum cTnT (4) or CK-MB activity (5) predicting myocardial infarction or death in uremic patients. The results of studies using current methods on large numbers of patients are eagerly awaited.
No takes yet. Share an insight, caveat, or question.
McNeil et al. (1998) conducted a letter in End-stage renal disease (hemodialysis) (n=81). Increased serum cTnT (>0.1 μg/L) vs. cTnT within reference values was evaluated on Mortality. In 81 hemodialysis patients followed for 20 months, increased serum cTnT was not associated with an increase in mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: